Physician profile
Wayne D Gross
NPI 1013916717
$11,826.74
in general payments reported to CMS, 2019-2025
26 companies · $1,122 in 2025
The $1,122 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,888 · 2020: $1,570 · 2021: $1,754 · 2022: $1,934 · 2023: $1,464 · 2024: $2,094 · 2025: $1,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,680.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,579.87 | 2019-2024 | Xarelto |
| Amgen INC. | $1,280.08 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $1,173.95 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,131.11 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $1,008.66 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $644.39 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals Lp | $577.84 | 2019-2025 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $569.49 | 2019-2025 | Lifevest |
| Amarin Pharma, INC. | $533.43 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $360.40 | 2019-2023 | |
| Abbott Laboratories | $329.23 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $311.20 | 2021-2025 | |
| Bridgebio Pharma, INC. | $271.65 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $207.49 | 2020-2025 | Nexletol |
| Scpharmaceuticals INC. | $169.46 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $156.45 | 2023-2024 | Watchman Access System |
| Pfizer INC. | $133.29 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $109.95 | 2019 | |
| Atricure, INC. | $72.35 | 2025 | Synergy Ablation System, Atriclip Laa Exclusion System |
| Kestra Medical Technology Services, INC. | $54.13 | 2023 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $44.24 | 2024 | Arcalyst |
| Abiomed | $34.15 | 2024 | Impella |
| Philips North America LLC | $32.06 | 2023-2024 | (5091) Amb Mon & Diag Und |
| Astellas Pharma US INC | $14.87 | 2019 | |
| Daiichi Sankyo INC. | $13.51 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.